Loading...
This record has been deleted. Since it is linked to a published record, it is available here for reference purposes only.
Click here to view the deleted recordThis document has been updated. This is not the latest published version. Click here to view the latest version of the record.
Country's Decision or any other Communication
(DEC)
last updated: 07 Aug 2019
No
APP202371 Decision
EN
16 Apr 2019
No
- Decision on LMOs for intentional introduction into the environment (according to Article 10 or domestic regulatory framework)
No
Yes
-
Person:Mr Alan CarterGeneral Manager,PO Box 12851 PenroseAuckland,
, New ZealandPhone: +64 9 5801810,Fax: +64 9 5801811,Email: alan.carter@sanofi.com,Website: https://www.sanofi.com.au/en,Related OrganizationSanofi New Zealand ()Private sector (business and industry)PO Box 12851 PenroseAuckland,
, New ZealandPhone: +64 9 5801810,Fax: +64 9 5801811,Email: alan.carter@sanofi.com,Website: https://www.sanofi.com.au/en,
No
Yes
Yes
Approval of the import and/or use of the LMO(s) without conditions
-
BCH-LMO-SCBD-114728-1 Living Modified Organism Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV)Sanofi-Aventis New Zealand Limited | Modified viral epitopes
-
BCH-RA-NZ-115092-1 Risk Assessment generated by a regulatory process EPA staff assessment report on application APP202371 - To import and release a genetically modified live-attenuated vaccine (IMOJEV®) to protect humans against Japanese encephalitis.Imojev (Japanese Encephalitis Chimeric Virus Vaccine; JE-CV) | JEV SA14-14-2, YFV 17D
- APP202371 decision [ English ]
